Low-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases.

Low-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases. J Crohns Colitis. 2019 Mar 19;: Authors: Borren NZ, Luther J, Colizzo FP, Garber JG, Khalili H, Ananthakrishnan AN Abstract BACKGROUND AND AIMS: Methotrexate [MTX] is a well-known immunomodulator in the treatment of inflammatory bowel disease [IBD] and is often combined with biologic agents. The ideal MTX dose for combination therapy has not been determined. This study aimed to investigate the effect of varying doses of MTX on efficacy and safety outcomes when…

Read More

The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis.

The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. J Crohns Colitis. 2019 Feb 14;: Authors: Sands BE, Cheifetz AS, Nduaka CI, Quirk D, Wang W, Maller E, Friedman GS, Su C, Higgins PDR Abstract In order to identify the practical implications for both health care practitioners and patients in understanding differences between the results of trials assessing therapies for ulcerative colitis [UC], we reviewed clinical trials of therapies for moderate to severe UC, with a focus on trial design. Over time, patient populations in UC trials…

Read More

Ileal Gene Expression Data from Crohn’s Disease Small Bowel Resections Indicate Distinct Clinical Sub-Groups.

Related Articles Ileal Gene Expression Data from Crohn’s Disease Small Bowel Resections Indicate Distinct Clinical Sub-Groups. J Crohns Colitis. 2019 Mar 16;: Authors: Potdar AA, Li D, Haritunians T, VanDussen KL, Fiorino MF, Liu TC, Stappenbeck TS, Fleshner P, Targan SR, McGovern DPB, Bilsborough J Abstract BACKGROUND AND AIMS: Heterogeneity in Crohn’s disease (CD) provides a challenge for development of effective therapies. Our goal was to define a unique molecular signature for severe, refractory CD to enable precision therapy approaches to disease treatment and facilitate earlier intervention in complicated disease.…

Read More

Role of Fecal Microbiota Transplantation for Maintenance of Remission in Patients with Ulcerative Colitis: A Pilot Study.

Related Articles Role of Fecal Microbiota Transplantation for Maintenance of Remission in Patients with Ulcerative Colitis: A Pilot Study. J Crohns Colitis. 2019 Mar 11;: Authors: Sood A, Mahajan R, Singh A, Midha V, Mehta V, Narang V, Singh T, Pannu AS Abstract OBJECTIVES: To study the role of fecal microbiota transplantation (FMT) in maintenance of remission in ulcerative colitis (UC). METHODS: In this pilot study, patients with UC in clinical remission after multi-session FMT were randomly allocated to either maintenance FMT or placebo colonoscopic infusion every 8 weeks, for…

Read More

Risk of malignant cancers in inflammatory bowel disease.

Risk of malignant cancers in inflammatory bowel disease. J Crohns Colitis. 2019 Mar 15;: Authors: Loo SY, Vutcovici M, Bitton A, Lakatos PL, Azoulay L, Suissa S, Brassard P Abstract OBJECTIVES: To explore the trends and the predictors of incident malignant cancer among patients with inflammatory bowel disease (IBD). METHODS: We identified a cohort of all patients with incident IBD in Quebec, Canada, from 1998 to 2015, using provincial administrative healthcare databases (RAMQ and Med-Echo). Annual incidence rates (IRs) of cancer were calculated using Poisson regression and were compared to…

Read More

Novel Leucocyte/Thrombocyte Apheresis for Induction of Steroid-Free Remission in Ulcerative Colitis: A Controlled Randomized Pilot Study.

Related Articles Novel Leucocyte/Thrombocyte Apheresis for Induction of Steroid-Free Remission in Ulcerative Colitis: A Controlled Randomized Pilot Study. J Crohns Colitis. 2019 Mar 13;: Authors: Kruis W, Nguyen P, Morgenstern J, Ramlow W, Dignaß A, Stallmach A, Drebber U Abstract BACKGROUND AND AIMS: In active ulcerative colitis [UC] refractory to mesalazine, escalation to either steroids or immunosuppression is common practice. The efficacy and safety of alternative escalation therapy with a novel leukocyte apheresis device were studied. METHODS: This was a prospective, randomized, controlled multicentre pilot study comparing leukocyte apheresis with…

Read More

Early Initiation of Anti-Tnf is Associated with Favourable Long-Term Outcome in Crohn’s Disease: 10-Year-Follow-Up Data from the Swiss IBD Cohort Study.

Related Articles Early Initiation of Anti-Tnf is Associated with Favourable Long-Term Outcome in Crohn’s Disease: 10-Year-Follow-Up Data from the Swiss IBD Cohort Study. J Crohns Colitis. 2019 Mar 07;: Authors: Frei R, Fournier N, Zeitz J, Scharl M, Morell B, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L, Swiss IBD Cohort Study Group Abstract BACKGROUND AND AIMS: The optimal timing of treatment escalation in Crohn’s disease (CD) remains a challenge and very little is known about its long-term development following early versus…

Read More

Enterotoxigenic Clostridium perfringens Infection as an Adverse Event After Faecal Microbiota Transplantation in Two Patients With Ulcerative Colitis and Recurrent Clostridium difficile Infection: A Neglected Agent in Donor Screening.

Enterotoxigenic Clostridium perfringens Infection as an Adverse Event After Faecal Microbiota Transplantation in Two Patients With Ulcerative Colitis and Recurrent Clostridium difficile Infection: A Neglected Agent in Donor Screening. J Crohns Colitis. 2019 Mar 10;: Authors: Azimirad M, Yadegar A, Asadzadeh Aghdaei H, Kelly CR PMID: 30852608 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30852608?dopt=Abstract

Read More

Early dose optimization of golimumab in nonresponders to induction treatment for ulcerative colitis is effective and supported by pharmacokinetic data.

Related Articles Early dose optimization of golimumab in nonresponders to induction treatment for ulcerative colitis is effective and supported by pharmacokinetic data. J Crohns Colitis. 2019 Mar 07;: Authors: Philip G, Cornillie F, Adedokun JO, Melsheimer R, Rutgeerts P, Colombel JF, Marano C Abstract BACKGROUND AND AIMS: In nonresponders to golimumab induction for ulcerative colitis, we assessed clinical response rates and golimumab serum concentrations when the 100 mg dose is used early in the course of maintenance.Methods: This post-hoc analysis of golimumab maintenance dosing (in the PURSUIT-M study) examined clinical…

Read More
<< Go Back